![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
JSI-1187 is a selective and orally administered small molecule inhibitor of ERK1 and ERK2. In preclinical studies, JSI-1187 demonstrated high potency against a variety of tumors with MAPK pathway mutations.
Lead Product(s): JSI-1187,Dabrafenib Mesylate
Therapeutic Area: Oncology Product Name: JSI-1187
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023